Mesoblast Ltd
Company Profile
Business description
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUST: +61 396396036
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
73
Stocks News & Analysis
stocks
Shorts circle BHP ahead of listing unification: ASX’s most shorted stocks
stocks
Mayne Pharma woes to persist for 2020
stocks
CSL remains favourite, but biotech field broadening
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,828.70 | 56.70 | 0.65% |
CAC 40 | 7,737.93 | 75.34 | 0.98% |
DAX 40 | 23,774.47 | 101.18 | 0.43% |
Dow JONES (US) | 44,446.42 | 48.52 | -0.11% |
FTSE 100 | 8,765.77 | 19.56 | -0.22% |
HKSE | 24,221.41 | 149.13 | 0.62% |
NASDAQ | 20,352.47 | 149.58 | 0.74% |
Nikkei 225 | 39,762.48 | 223.85 | -0.56% |
NZX 50 Index | 12,784.29 | 49.76 | 0.39% |
S&P 500 | 6,210.96 | 12.95 | 0.21% |
S&P/ASX 200 | 8,597.70 | 56.60 | 0.66% |
SSE Composite Index | 3,454.79 | 2.95 | -0.09% |